David W Boulton (David Boulton)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Topics

Acute Heart Failure

Hypertrophic Cardiomyopathy

Top Venues

Diabetes, obesity & metabolism

Journal of clinical pharmacology

CPT: pharmacometrics & systems pharmacology

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Christine Gong, Lynn N Bertagnolli, David W Boulton, Paola Coppola
A literature review of drug transport mechanisms during lactation. CPT: pharmacometrics & systems pharmacology (2024)
Lindsay E Clegg, Lulu Chu, Mats Någård, David W Boulton, Robert C Penland
Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model-informed drug development case study. CPT: pharmacometrics & systems pharmacology (2023)
Johanna Melin, Joanna Parkinson, Bengt Hamrén, Robert C Penland, David W Boulton, Weifeng Tang
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus. British journal of clinical pharmacology (2023)
Christine Gong, Lynn N Bertagnolli, David W Boulton, Paola Coppola
A Literature Review of Changes in Phase II Drug-Metabolizing Enzyme and Drug Transporter Expression during Pregnancy. Pharmaceutics 15 (11) (2023)
Robert C Penland, Johanna Melin, David W Boulton, Weifeng Tang
Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus. Journal of clinical pharmacology (2022)
Hongtao Yu, Sanchita Basu, Weifeng Tang, Robert C Penland, Peter J Greasley, Jan Oscarsson, David W Boulton, Melissa K Hallow
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. Journal of clinical pharmacology (2021)
Millie Shah, Leonid A Stolbov, Tatiana Yakovleva, Weifeng Tang, Victor Sokolov, Robert C Penland, David W Boulton, Joanna Parkinson
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. Diabetes, obesity & metabolism 23 (4) (2021)
Hongtao Yu, Weifeng Tang, Peter J Greasley, Robert C Penland, David W Boulton, Melissa K Hallow
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis. Journal of clinical pharmacology 61 (5) (2020)
Tatiana Yakovleva, Victor Sokolov, Lulu Chu, Weifeng Tang, Peter J Greasley, Helena Peilot Sjögren, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W Boulton, Robert C Penland
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes, obesity & metabolism 21 (12) (2019)
Victor Sokolov, Tatiana Yakovleva, Shinya Ueda, Joanna Parkinson, David W Boulton, Robert C Penland, Weifeng Tang
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus. Diabetes, obesity & metabolism 21 (4) (2018)